Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Albumin Therapy (TAT 4) in Cirrhosis
NCT04058613Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2019
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in Liver cirrhosis (LC) comparing Albumin with Placebo (2 arms). Primary endpoint: Transplant/Transintrahepatic Portosystemic Shunt (TIPS) free survival at 12 months. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04058613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058613.